Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes
Status:
Unknown status
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
We are evaluating the efficacy of the association of Low dose Cytarabine in association with
Bortezomib in the treatment of patients diagnosed with high risk Myelodysplastic syndromes.
Our aim is to decrease transfusion requirements and if possible induce a complete or at least
a partial remission.